E
E M Guerra
Publications - 14
Citations - 1333
E M Guerra is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 735 citations.
Papers
More filters
Journal ArticleDOI
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman,Amit M. Oza,Domenica Lorusso,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Andrew R Clamp,Giovanni Scambia,Alexandra Leary,Robert W Holloway,Margarita Amenedo Gancedo,Peter C.C. Fong,Jeffrey C. Goh,David M. O'Malley,Deborah K. Armstrong,Jesus Garcia-Donas,Elizabeth M. Swisher,Anne Floquet,Gottfried E. Konecny,Iain A. McNeish,Clare L. Scott,Terri Cameron,Lara Maloney,Jeff Isaacson,Sandra Goble,Caroline Grace,Thomas Harding,Mitch Raponi,James Sun,Kevin K. Lin,Heidi Giordano,Jonathan A. Ledermann,Martin Buck,A Dean,Michael Friedlander,J C Goh,Paul R. Harnett,G Kichenadasse,C L Scott,H Denys,Luc Dirix,Ignace Vergote,Laurie Elit,Prafull Ghatage,Amit M. Oza,Marie Plante,Diane Provencher,J I Weberpals,Stephen Welch,A Floquet,Laurence Gladieff,Florence Joly,A Leary,Alain Lortholary,Jean-Pierre Lotz,J. Medioni,Olivier Tredan,Benoit You,A El-Balat,C Hänle,P Krabisch,T Neunhöffer,M Pölcher,Pauline Wimberger,Amnon Amit,S Kovel,M Leviov,Tamar Safra,Ronnie Shapira-Frommer,Salomon M. Stemmer,Alessandra Bologna,N Colombo,Domenica Lorusso,Sandro Pignata,Roberto Sabbatini,G Scambia,Stefano Tamberi,Claudio Zamagni,P C Fong,A O'Donnell,M Amenedo Gancedo,A Casado Herraez,J Garcia-Donas,E M Guerra,A Oaknin,I Palacio,Iris L. Romero,A Sanchez,Susana Banerjee,A Clamp,Y Drew,Hani Gabra,D Jackson,Jonathan A. Ledermann,I A McNeish,Christine Parkinson,Melanie E Powell,C Aghajanian,D K Armstrong,Michael J. Birrer,Mary K. Buss,Setsuko K. Chambers,L-m Chen,Robert L. Coleman,R W Holloway,G E Konecny,L Ma,Mark A. Morgan,R T Morris,David G. Mutch,D M O'Malley,B M Slomovitz,E M Swisher,T Vanderkwaak,M Vulfovich +116 more
TL;DR: This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Journal ArticleDOI
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Vicky Makker,Nicoletta Colombo,Antonio Casado Herraez,Alessandro D. Santin,Emeline Colomba,Keiichi Fujiwara,Sandro Pignata,Sally Baron-Hay,Isabelle Ray-Coquard,Ronnie Shapira-Frommer,Kimio Ushijima,Jun Sakata,Kan Yonemori,Yong Man Kim,E M Guerra,Ulus Ali Sanli,Mary McCormack,Alan D Smith,Stephen Oʼ Keefe,Steven Bird,Lea Dutta,Robert J. Orlowski,Domenica Lorusso +22 more
TL;DR: Lenvatinib plus pembrolizumab led to significantly longer progression-free survival and overall survival than chemotherapy among patients with advanced endometrial cancer.
Journal ArticleDOI
Prospective Real-World Gynaecological Cancer Clinical Registry with Associated Biospecimens: A Collaborative Model to Promote Translational Research between GEICO and the Spanish Biobank Network
José Antonio López-Guerrero,Marta Mendiola,Jose Alejandro Perez-Fidalgo,Ignacio A. Romero,Ana Torres,Delia Recalde,Elena M. Molina,César Gómez-Raposo,Ana M. Levin,Ana B. Herrero,Jesus Alarcón,C. Esteban,Gloria Marquina,María J. Rubio,E M Guerra,Luisa Sanchez-Lorenzo,Fernando Gálvez-Montosa,Ana de Juan,Cristina Maria Churruca,Alejandro Gallego,Antonio González-Martín +20 more
TL;DR: This collaborative project aims to promote research by providing broad access to high-quality clinical data and biospecimens for future research according to the needs of investigators and to increase diagnostic and therapeutic opportunities for gynaecological cancer patients in Spain.
Journal ArticleDOI
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme.
Juan Cueva,I Palacio,Cristina Maria Churruca,Ana B. Herrero,Beatriz Pardo,Manuel Constenla,Ana Santaballa,Luis Manso,Purificacion Estevez,Constanza Maximiano,Marta Legerén,Gloria Marquina,Ana de Juan,Maria Quindós,L. Manso Sánchez,Arantzazu Barquin,Isaura Fernández,Cristina Martin,A. Juárez,Teresa Blanco Martín,Y. García,A. Yubero,Alejandra Gallego,Alejandra Martínez Bueno,E M Guerra,Antonio González-Martín +25 more
TL;DR: In this article , the authors describe patient characteristics, effectiveness and safety in a real-world population treated with niraparib in the Spanish expanded-access programme, including women with platinum-sensitive recurrent high-grade serous ovarian cancer.
Journal ArticleDOI
Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study
Andres Poveda,Raquel López-Reig,Ana Oaknin,Andrés Redondo,María J. Rubio,E M Guerra,Lorena Fariñas-Madrid,Alejandro Gallego,Victor Rodriguez-Freixinos,Antonio Fernandez-Serra,Oscar Juan,Ignacio A. Romero,José Antonio López-Guerrero +12 more
TL;DR: The POLA study provides evidence that the administration of lurbinectedin and olaparib is feasible and tolerable, with a DCR of 72.6%.